Article Text

Download PDFPDF
Therapeutic options for systemic right ventricular failure
  1. P Szymañski,
  2. A Klisiewicz,
  3. P Hoffman
  1. Institute of Cardiology, Warsaw, Poland
  1. Correspondence to Dr P Szymañski, Alpejska 42, Warsaw 04 628, Poland; p.szymanski{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

To the editor: In the recent paper presenting the latest insights into the therapeutic options for patients with systemic right ventricles, Winter et al1 argued that “the pragmatic use of angiotensin converting enzyme inhibitors and β blockers in these patients seems appropriate”. However, they also concluded that “the evidence base for the implementation of left ventricular failure treatment regimens in patients with a systemic right ventricle is poor” and that “most studies were underpowered, had short follow-up periods, or had a retrospective study set-up”.

There is, however, another important reason for the failure to demonstrate the efficacy of angiotensin converting enzyme inhibitors, …

View Full Text


  • Provenance and peer review Not commissioned; not externally peer reviewed.